Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Perhaps the agonistic aspects of 2-73 on M1/M4 are being underappreciated?
http://www.voanews.com/a/new-alzheimers-drug-slows-memory-loss-extends-life-mouse-model/3643150.html
I think Missling realized how long of a process it will be to negotiate the best deal; therefore, raised the additional $11M to keep their trial plans on schedule.
I don't; just saw it on CNBC.
Biogen announces its new CEO. It's not Missling.
There are probably some institutions who don't buy shares of companies, especially young biotechs, with PPS under $5; however, I believe there are more institutions who don't buy biotechs unless they are in at least a Phase 3 trial. I expect with the announcement of P2/3 for Alz, we'll start seeing larger demand and participation from institutions.
Truly is amazing that this can be so heavily manipulated.
Hey FDA! Can we please get a BTD, SPA and/or Fast-track designation?!
Okay, now where was I?
I just now accessed and downloaded from Anavex's home page. If you can't get it, I have a copy.
EDIT: I see you were able to access a copy.
WELL SAID!
You need to revisit the company presentation and pipeline.
LOL! Gimmick? Really...the company puts "gimmicks" in its 10-Ks?
This paragraph about competition is worth pasting...
"Each of our competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval, and pharmaceutical product manufacturing and marketing than we do. With these additional resources, our competitors will be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in large part on our ability to acquire funding for our research and development. To continue to acquire funding for our research and development, we will likely have to show progress toward our goals and we will eventually be expected to develop a compound that may result in a transaction with another pharmaceutical company."
I especially like the following paragraph taken from the pipeline section...
"Our proprietary SIGMACEPTOR™ Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative nature, including Alzheimer’s disease, as well as of neurodevelopmental nature, like Rett syndrome, a rare disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease."
PROPRIETARY!
There are now 39,610,967 shares issued and outstanding as of December 12, 2016.
Here's the most recent... up to $100M (6.7M shares), which would require an avg PPS of $15 to hit $100M.
https://www.sec.gov/Archives/edgar/data/1314052/000161577416007004/s104014_s3a.htm
I thought there was a more recent agreement this year???
Certainly the time remaining this year reduces the probability of a near term PR, but the fact they issued shares to raise funds recently might suggest they're nearing a trial. We'll see...
If my recollection is correct, up to $100M.
What are the probabilities for any of the below announcements happening this year?
1. Rett's P2 trial
2. Parkinson's P2 trial
3. Alz P2b/3 trial
4. Partnership
5. Grant
Anavex would be the last biotech that Cramer would have on his show. He's involved in, or a least knows about, the attacks; their money is elsewhere.
Data are inconclusive? Really? For anyone who can read a chart, the MMSE and ADL graphs are rather convincing. Add to that the super responders and all of the positive comments from caregivers regarding their loved ones' improvements.
Unfortunately, the company didn't PR the CTAD findings and results to the investment community, to increase awareness of progress. Missed opportunity.
Thanks for spreading the word!
I'm in Xena's camp: Barring any PRs, this will likely be held below $5 through Friday (options expiration).
Yes, this gives the company more runway to continue their trial activities while working on grants and/or partnerships.
Thanks! I commented back to the publisher that they omitted the "n't"...
"Obviously this is a big task, and one that hundreds of companies have been able to complete successfully in the past two decades alone,"
Has this interview with Macfarlane been posted? Go to the 39 min mark...
http://www.abc.net.au/worldtoday/content/2016/s4591557.htm
So true... they are the sacrificial lambs.
The only way it could have been better is if they caught AF, JF and the rest of TheStreet cabal.
For those who don't believe manipulation is a reality in micro-cap stocks...
http://www.marketwatch.com/story/two-traders-arrested-over-alleged-manipulation-of-more-than-2000-stocks-2016-12-12?link=sfmw_fb
Like whom?
I see your MJFF and raise you an Aussie. They've already confirmed the P2b/3 trial and are soliciting for patients.
I would think so. That's why I believe we should be hearing that horn soon.
I think we'll be hearing that horn sooner than later. It's too small of an amount to be a corporate partner, so my guess is a grant...either AU, MJFF or Rett's.
Thanks for the summary; I concur with your assessment. How is the exclusivity applied? Can a competitor begin developing a copycat drug in that timeframe? Can they begin their own trials (just not P3)?
If they can't begin trials during the exclusivity period, then effectively it's a 7 - 9 year exclusivity period, due to the several trial phases.
Don't think so... there was no filing of this.
It seemed to me that the call was primarily for the new analysts coming on board, catching them up. Just your typical quarter-end conf-call.
Indeed... We can't stop the "games", but hopefully they will now be played at a much higher PPS, like in the teens or perhaps the twenties!
Just might hit $5 today...
My best guess from where the $8M came is the AU government, as it was confirmed earlier by email that their P2b/3 trial will begin by midyear.
Perhaps each participating country will elect to fund their own trials???
Would like to see the first funds being doled out from the new Cures Act go to Anavex!
If he's not publishing anything it's because he's being TOLD not to, nor being provided the write-up or ammo. Perhaps they're waiting for the conference call to come up with their next contrived FUD article.
It's fairly well understood that AF and others work for the cabal. They are the mouthpieces who are paid to distort the facts and spread FUD as cover for the related short attacks. Get used to it, until the SEC/FBI gather them up.